Publications by authors named "Takehiro Okuno"
Video-assisted thoracoscopic surgery is a widely recommended treatment for empyema in advanced stages. However, only a few studies have evaluated prognostic factors among patients with empyema who underwent video-assisted thoracoscopic surgery. Furthermore, no studies have evaluated predictors of direct discharge home.
View Article and Find Full Text PDFBackground: Because of limitations in previous randomised controlled trials and observational studies, the effectiveness of immediate video-assisted thoracoscopic surgery (VATS) for patients with empyema in real-world settings remains unclear.
Objective: This study aimed to evaluate whether immediate VATS improves clinical outcomes in patients with empyema.
Methods: This multicentre retrospective cohort study included 744 patients with physician-diagnosed empyema from six hospitals between 2006 and 2021.
Chest computed tomography is performed in patients with empyema for various reasons. However, its predictive ability for patient outcomes in empyema has not been evaluated. To evaluate the predictive ability of computed tomography findings (pleural thickness, loculation, interlobar pleural effusion, lung abscess, and bronchopleural fistula) for 90-day mortality in empyema.
View Article and Find Full Text PDFArticle Synopsis
- Afatinib is a treatment for EGFR mutation-positive non-small-cell lung cancer (NSCLC) that often requires dose adjustments due to side effects; lowering the dose may reduce these adverse events without compromising effectiveness.
- In a phase II trial with 46 patients, the study started afatinib at a low dose of 20 mg/day, with the option to increase it, focusing on progression-free survival as the main outcome.
- Results showed a median progression-free survival of 15.2 months and a high one-year overall survival rate of 95.6%, indicating that a lower starting dose of afatinib is both effective and well-tolerated, but further research is needed.
Background: Nanoparticle albumin-bound paclitaxel (nab-PTX), which avoids toxicities associated with a vehicle used in solvent-based PTX, has already shown safety and efficacy in patients with non-small cell lung cancer (NSCLC).
Methods: A phase II study was performed to assess the safety and efficacy of nab-PTX monotherapy as second-line chemotherapy after cytotoxic anticancer drugs for previously treated advanced NSCLC. Thirty-two patients with advanced NSCLC who had previously undergone 1 regimen of cytotoxic anticancer drugs were enrolled.